Advertisement

Journal of General Internal Medicine

, Volume 34, Issue 8, pp 1383–1384 | Cite as

Secular Trends in Long-Term Oral Bisphosphonate Use

  • Nathan Juergens
  • Bruce Ettinger
  • Rita Hui
  • Malini Chandra
  • Joan C. LoEmail author
Concise Research Reports

INTRODUCTION

Bisphosphonates (BP) have been used for over 20 years to treat osteoporosis, based on strong evidence of fracture risk reduction in high-risk women treated up to 5 years.1 Although discontinuation rates are high in the first year, greater treatment adherence is associated with increased fracture risk reduction. However, the optimal duration of BP therapy remains unclear. Since 2008, national declines in the number of patients receiving BP therapy have been observed,2,3 with total dispensed BP prescriptions falling from 31 to 14 million between 2008 and 2012.3 A confluence of factors may account for this, including concerns for rare adverse side effects2 and revised national practice guidelines reducing treatment of low-risk women4,5; these same factors may have prompted patients taking BP and providers prescribing BP to interrupt treatment. This report examines secular trends in long-term BP continuation and examines whether late non-adherence is more prominent in the...

Notes

Funding

This study received financial support from the Kaiser Permanente Northern California Community Benefit Grant and National Institute of Aging and National Institute of Arthritis, Musculoskeletal and Skin Diseases at the National Institutes of Health (R01AG047230, S1).

Compliance with Ethical Standards

This study was conducted within Kaiser Permanente Northern California (KPNC) and approved by the KPNC Institutional Review Board.

Conflict of Interest

The following conflicts of interest are reported: Joan Lo has received research funding from Amgen, Inc., and Sanofi Aventis and Malini Chandra has received research funding from Amgen, not pertaining to this study; Bruce Ettinger has served as an expert witness pertaining to litigation involving teriparatide (Teva Pharmaceuticals). The remaining authors have no conflicts of interest to disclose.

References

  1. 1.
    Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122:S14–21.CrossRefGoogle Scholar
  2. 2.
    Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015;30:2179–87.CrossRefGoogle Scholar
  3. 3.
    Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423–8.CrossRefGoogle Scholar
  4. 4.
    Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2008.Google Scholar
  5. 5.
    Lee DR, Ettinger B, Chandra M, Hui RL, Lo JC. Changing patterns in oral bisphosphonate initiation in women between 2004 and 2012. J Am Geriatr Soc. 2017;65:656–8.CrossRefGoogle Scholar
  6. 6.
    Hui RL, Adams AL, Niu F, et al. Predicting adherence and persistence with oral bisphosphonate therapy in an integrated health care delivery system. J Manag Care Spec Pharm. 2017;23:503–12.PubMedPubMedCentralGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  • Nathan Juergens
    • 1
  • Bruce Ettinger
    • 2
  • Rita Hui
    • 3
  • Malini Chandra
    • 2
  • Joan C. Lo
    • 1
    • 2
    Email author
  1. 1.Department of MedicineKaiser Permanente Oakland Medical CenterOaklandUSA
  2. 2.Division of ResearchKaiser Permanente Northern CaliforniaOaklandUSA
  3. 3.Pharmacy Outcomes Research GroupKaiser Permanente CaliforniaOaklandUSA

Personalised recommendations